Navigation Links
FDA Approves Latuda to Treat Schizophrenia in Adults
Date:10/28/2010

SILVER SPRING, Md., Oct. 28 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Schizophrenia affects about 1 percent of the U.S. population, ages 18 years and older, in a given year. The most prominent symptoms include hallucinations, delusions, disordered thinking and behavior, and suspiciousness. Hearing voices that other people don't hear is the most common type of hallucination. These experiences can make people with the disorder fearful and withdrawn.

"Schizophrenia can be a devastating illness requiring lifelong treatment," said Thomas Laughren, M.D., director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research. "Some patients do not respond well to certain types of drug therapy, so it is important to have multiple treatment options available."

Latuda is included in the atypical antipsychotic class of drugs. All atypical antipsychotics contain a boxed warning alerting prescribers to an increased risk of death associated with off-label use of these drugs to treat behavioral problems in older people with dementia-related psychosis. No drug in this class is approved to treat patients with dementia-related psychosis.

Four six-week controlled studies of adults with schizophrenia demonstrated the effectiveness and safety of Latuda. In the trials, patients treated with Latuda had fewer symptoms of schizophrenia than those taking an inactive pill (placebo).  

The most common adverse reactions reported by those in clinical trials were drowsiness, feelings of restlessness and the urge to move (akathisia), nausea, movement abnormalities such as tremors, slow movement, or muscle stiffness (Parkinsonism), and agitation.

Latuda is manufactured by Sunovion Pharmaceuticals Inc. of Fort Lee, N.J.

For information:

National Institute of Mental Health: Schizophrenia

http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Sandy Walsh, 301-796-4669; sandy.walsh@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA




'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Additional Medical Indication for Sprycel
2. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
3. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
4. FDA Approves Botox to Treat Chronic Migraine
5. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
6. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
7. FDA Approves Combination Contraceptive Containing a Folate
8. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
9. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
10. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
11. FDA Approves Pediatric Use of Chemical Poisoning Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  Bayer has awarded grants totaling more than ... of its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. ... Philadelphia and Uniformed Services University of the Health ... winners. Grant recipients were announced last night during a reception ... Congress, Berlin, Germany . ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The most common surgical techniques ... of life five years after injury, according to research presented today at the ... Canada. The study followed patients for five years following surgery. , “Orthopaedic surgeons ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid ... cancer that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens ... reoccurrence and relapse. With such a challenging diagnosis that requires immediate action, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Remote ... which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... remote participants for real-time collaboration and immediate decision-making requirements. While never sharing ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... about the introduction of bipartisan House and Senate legislation in support of providing ... Congresswoman Robin Kelly (D-IL) introduced H.R. 2408, the “Protecting Girls’ Access to Education ...
(Date:7/20/2017)... ... July 20, 2017 , ... There’s a lot of confusing lingo out ... are the same thing. But it’s crucial to understand both the differences and similarities ... to Kaixuan Liu, MD, PhD, founder and president of Atlantic Spine Center . ...
Breaking Medicine News(10 mins):